Bagsvaerd, Denmark-based Novo Nordisk A/S' chief medical officer, Todd Hobbs, told BioWorld it "won't be too much longer" – probably a week or so – before the firm sets pricing of oral once-daily Rybelsus (semaglutide) in type 2 diabetes, approved Friday thanks to a priority review voucher that guaranteed a greased path for the first non-injected glucagon-like peptide (GLP-1) receptor protein therapy.